In summary, our data demonstrate that simultaneous inhibition of CDK9 and the KRAS/MAPK pathway reciprocally strengthen the anticancer effect of each monotherapy in preclinical models of KRAS‐mutant cancers, including those with KRASi resistance. Here, KRAS is linked to cancer.